vs
博士伦（BLCO）与Brightstar Lottery PLC（BRSL）财务数据对比。点击上方公司名可切换其他公司
Brightstar Lottery PLC的季度营收约是博士伦的1.8倍（$2.5B vs $1.4B），Brightstar Lottery PLC净利率更高（5.9% vs -4.1%，领先10.0%），博士伦自由现金流更多（$60.0M vs $-415.0M）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
BLCO vs BRSL — 直观对比
营收规模更大
BRSL
是对方的1.8倍
$1.4B
净利率更高
BRSL
高出10.0%
-4.1%
自由现金流更多
BLCO
多$475.0M
$-415.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $2.5B |
| 净利润 | $-58.0M | $147.0M |
| 毛利率 | — | — |
| 营业利润率 | 8.0% | 11.9% |
| 净利率 | -4.1% | 5.9% |
| 营收同比 | 9.8% | — |
| 净利润同比 | -1833.3% | — |
| 每股收益（稀释后） | $-0.16 | $0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOBRSL
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.1B | — |
净利润BLCOBRSL
| Q4 25 | $-58.0M | $147.0M | ||
| Q3 25 | $-28.0M | — | ||
| Q2 25 | $-62.0M | — | ||
| Q1 25 | $-212.0M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-151.0M | — | ||
| Q1 24 | $-167.0M | — |
营业利润率BLCOBRSL
| Q4 25 | 8.0% | 11.9% | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -7.3% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 0.5% | — |
净利率BLCOBRSL
| Q4 25 | -4.1% | 5.9% | ||
| Q3 25 | -2.2% | — | ||
| Q2 25 | -4.9% | — | ||
| Q1 25 | -18.6% | — | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | -12.4% | — | ||
| Q1 24 | -15.2% | — |
每股收益（稀释后）BLCOBRSL
| Q4 25 | $-0.16 | $0.74 | ||
| Q3 25 | $-0.08 | — | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.60 | — | ||
| Q4 24 | $-0.00 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $-0.43 | — | ||
| Q1 24 | $-0.48 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $1.4B |
| 总债务越低越好 | $5.0B | $4.1B |
| 股东权益账面价值 | $6.4B | $875.0M |
| 总资产 | $14.0B | $9.2B |
| 负债/权益比越低杠杆越低 | 0.78× | 4.64× |
8季度趋势，按日历期对齐
现金及短期投资BLCOBRSL
| Q4 25 | $383.0M | $1.4B | ||
| Q3 25 | $310.0M | — | ||
| Q2 25 | $266.0M | — | ||
| Q1 25 | $202.0M | — | ||
| Q4 24 | $305.0M | — | ||
| Q3 24 | $329.0M | — | ||
| Q2 24 | $285.0M | — | ||
| Q1 24 | $315.0M | — |
总债务BLCOBRSL
| Q4 25 | $5.0B | $4.1B | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCOBRSL
| Q4 25 | $6.4B | $875.0M | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.4B | — | ||
| Q4 24 | $6.5B | — | ||
| Q3 24 | $6.6B | — | ||
| Q2 24 | $6.5B | — | ||
| Q1 24 | $6.7B | — |
总资产BLCOBRSL
| Q4 25 | $14.0B | $9.2B | ||
| Q3 25 | $13.8B | — | ||
| Q2 25 | $13.8B | — | ||
| Q1 25 | $13.4B | — | ||
| Q4 24 | $13.5B | — | ||
| Q3 24 | $13.5B | — | ||
| Q2 24 | $13.3B | — | ||
| Q1 24 | $13.3B | — |
负债/权益比BLCOBRSL
| Q4 25 | 0.78× | 4.64× | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $-99.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $-415.0M |
| 自由现金流率自由现金流/营收 | 4.3% | -16.5% |
| 资本支出强度资本支出/营收 | 5.4% | 12.6% |
| 现金转化率经营现金流/净利润 | — | -0.67× |
| 过去12个月自由现金流最近4个季度 | $-66.0M | — |
8季度趋势，按日历期对齐
经营现金流BLCOBRSL
| Q4 25 | $136.0M | $-99.0M | ||
| Q3 25 | $137.0M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | $-25.0M | — | ||
| Q4 24 | $22.0M | — | ||
| Q3 24 | $154.0M | — | ||
| Q2 24 | $15.0M | — | ||
| Q1 24 | $41.0M | — |
自由现金流BLCOBRSL
| Q4 25 | $60.0M | $-415.0M | ||
| Q3 25 | $63.0M | — | ||
| Q2 25 | $-54.0M | — | ||
| Q1 25 | $-135.0M | — | ||
| Q4 24 | $-70.0M | — | ||
| Q3 24 | $94.0M | — | ||
| Q2 24 | $-57.0M | — | ||
| Q1 24 | $-26.0M | — |
自由现金流率BLCOBRSL
| Q4 25 | 4.3% | -16.5% | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.2% | — | ||
| Q1 25 | -11.9% | — | ||
| Q4 24 | -5.5% | — | ||
| Q3 24 | 7.9% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | -2.4% | — |
资本支出强度BLCOBRSL
| Q4 25 | 5.4% | 12.6% | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 6.1% | — |
现金转化率BLCOBRSL
| Q4 25 | — | -0.67× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
BRSL
暂无分部数据
